Charles River’s Biologics division is excited to announce the growth of its analytical facility in Shrewsbury, MA. In response to increasing client demand, this expansion brings North America’s bioassay offerings in line with those found in our Erkrath, Germany and Edinburgh, UK facilities. Expanding cGMP services in this region will help with shorter turnaround times, and can aid clients in keeping their projects within budget and on schedule. Other areas of expansion in Shrewsbury will include adding stability storage, along with doubling up in North America on liquid nitrogen space for cell banking needs. These additions are expected to become available during the second quarter of 2019.
This expanded capacity increases useable space five-fold, allowing us to keep pace with the growing interest in biologics development and related services. Along with higher capacity, the Shrewsbury site also offers analytical services ranging from mass spectrometry and formulation development to biophysical characterization, providing all necessary biologics services under one roof.
The Biologics facility recently celebrated its first anniversary and successfully completed FDA inspection in October of last year.
If you are interested in learning more about the facility or to inquire about any of the services offered in Shrewsbury please contact us at [email protected].